You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康臣藥業(01681.HK):SK-08片劑臨牀一期試驗完成首批受試者給藥
格隆匯 03-13 18:55

格隆匯3月13日丨康臣藥業(01681.HK)公吿,集團正在進行評估SK-08片劑的安全性、耐受性及藥代動力學特徵的臨牀一期試驗,首批受試者已成功用藥。

慢性腎病(CKD)是全球公共衞生的重大挑戰,嚴重危害人類健康。患病人數於中國已超逾1億人,且發病率呈現持續逐年上升趨勢。CKD患者的腎功能會逐漸衰退,最終可能發展為終末期腎病(ESRD),需要進行透析或腎臟移植。這對患者及其家人造成了巨大的身體、情緒及經濟負擔。

SK-08片劑是集團與其他藥業公司聯合開發的具有全球知識產權的1類創新藥,其獨特的作用機制為精準靶向可溶性鳥苷酸環化酶(sGC),不依賴一氧化氮的存在,促進cGMP生成,通過舒張血管平滑肌、增加腎臟血流供應、改善腎小球濾過率、抗炎和抗纖維化等多重生物學效應,減少蛋白尿,保護腎臟功能,並能調節腎臟重吸收,改善心功能,降低血栓形成風險。

在臨牀前試驗中,SK-08片劑顯著降低尿蛋白、改善腎臟功能與腎小球硬化,安全性耐受性良好。目前,全球範圍內尚無同類機制藥物獲批用於慢性腎病的治療。SK-08片劑有望填補這一空白,將為慢性腎病患者提供新的治療選擇。

集團展望推廣優先關注腎臟健康、及早篩查及預防,並積極探索創新治療方案,而首批受試者的成功用藥,標誌着集團在開發腎病創新療法方面的另一個重要里程碑。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account